

Herv Dombret

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5007366/herve-dombret-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

127
papers

14,478
citations

40
h-index

120
g-index

137
ext. papers

17,865
ext. citations

7
avg, IF

5.87
L-index

#	Paper	IF	Citations
127	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017 , 129, 424-447	2.2	2764
126	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010 , 115, 453-74	2.2	2483
125	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017 , 376, 836-847	59.2	978
124	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2015 , 16, 57-66	21.7	832
123	Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3244-54	2.2	733
122	Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2012 , 379, 1508-16	40	646
121	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet Oncology, The</i> , 2014 , 15, 986-96	21.7	410
120	A 17-gene stemness score for rapid determination of risk in acute leukaemia. <i>Nature</i> , 2016 , 540, 433-437	50.4	369
119	An update of current treatments for adult acute myeloid leukemia. <i>Blood</i> , 2016 , 127, 53-61	2.2	313
118	Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. <i>Blood</i> , 2002 , 100, 2357-66	2.2	287
117	HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). <i>Blood</i> , 2005 , 106, 274-86	2.2	285
116	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. <i>Lancet Haematology, the</i> , 2016 , 3, e186-95	14.6	276
115	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 2213-23	2.2	248
114	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. <i>Blood</i> , 2014 , 123, 3739-49	2.2	225
113	Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015 , 125, 3711-9	2.2	208
112	Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016 , 375, 1044-53	59.2	201
111	NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. <i>Blood</i> , 2009 , 113, 3918-24	2.2	170

110	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. <i>Journal of Clinical Oncology</i> , 2017 , 35, 185-193	2.2	167
109	Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4333-42	2.2	166
108	Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. <i>Blood</i> , 2016 , 128, 774-82	2.2	155
107	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2018 , 19, 889-903	21.7	145
106	Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. <i>Blood</i> , 2007 , 109, 5129-35	2.2	138
105	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. <i>Blood</i> , 2016 , 127, 2451-9	2.2	136
104	Gemtuzumab ozogamicin for acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. <i>Haematologica</i> , 2019 , 104, 113-119	6.6	132
103	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. <i>Haematologica</i> , 2016 , 101, 1524-1533	6.6	110
102	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , 2020 , 383, 2526-2537	59.2	100
101	Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. <i>Blood</i> , 2014 , 124, 1445-9	2.2	93
100	Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2683-2691	2.2	89
99	Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. <i>Blood</i> , 2015 , 125, 3447-54	2.2	80
98	IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. <i>Oncotarget</i> , 2015 , 6, 42345-53	3.3	78
97	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2514-2523	2.2	57
96	Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. <i>Journal of Clinical Oncology</i> , 2013 , 31, 321-7	2.2	55
95	MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. <i>Oncotarget</i> , 2014 , 5, 6280-8	3.3	54
94	Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. <i>Blood</i> , 2007 , 110, 2324-30	2.2	52
93	Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. <i>Blood</i> , 2019 , 134, 1351-1355	2.2	50

92	Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. <i>Blood</i> , 2014 , 124, 1312-9	2.2	49
91	A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 139-45 ²		47
90	The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. <i>Blood</i> , 2016 , 127, 2157-60	2.2	46
89	Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2017 , 130, 1832-1844	2.2	44
88	Chromosomal Abnormalities and Prognosis in -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2632-2642	2.2	40
87	Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial. <i>Oncotarget</i> , 2014 , 5, 916-32	3.3	40
86	Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. <i>Oncotarget</i> , 2015 , 6, 22812-21	3.3	37
85	Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. <i>Blood</i> , 2018 , 132, 187-196	2.2	36
84	An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. <i>Haematologica</i> , 2016 , 101, 732-40	6.6	36
83	Site- and allele-specific polycomb dysregulation in T-cell leukaemia. <i>Nature Communications</i> , 2015 , 6, 6094	17.4	35
82	Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 586-593	1.9	34
81	Hypomethylating Agents as a Therapy for AML. <i>Current Hematologic Malignancy Reports</i> , 2017 , 12, 1-10	4.4	34
80	Pediatric-like therapy for adults with ALL. <i>Current Hematologic Malignancy Reports</i> , 2014 , 9, 158-64	4.4	30
79	Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. <i>Cancer</i> , 2020 , 126, 304-310	6.4	28
78	Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 542-546	2.2	28
77	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1223-1230	2.2	27
76	Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2281-8	1.8	25
75	Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?. <i>Current Opinion in Hematology</i> , 2009 , 16, 92-7	3.3	25

74	Clinical relevance of mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. <i>Haematologica</i> , 2018 , 103, 822-829	6.6	24
73	Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia. <i>Cancer Discovery</i> , 2016 , 6, 972-85	24.4	24
72	P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. <i>Blood</i> , 2019 , 133, 280-284	2.2	24
71	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. <i>Blood</i> , 2018 , 132, 563-569	2.2	23
70	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. <i>Haematologica</i> , 2015 , 100, e128-31	6.6	22
69	Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2214-2222	1.9	20
68	Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. <i>European Journal of Cancer</i> , 2014 , 50, 1159-68	7.5	20
67	Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation. <i>Cancer Discovery</i> , 2018 , 8, 1614-1631	16.3	19
66	mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2019 , 104, 1617-1625	6.6	18
65	New insights in the management of elderly patients with acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2009 , 21, 589-93	4.2	18
64	Final Analysis of the ALFA 0701 Study. <i>Blood</i> , 2014 , 124, 376-376	2.2	17
63	Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL. <i>Clinical Cancer Research</i> , 2019 , 25, 2483-2493	12.9	15
62	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. <i>Blood Advances</i> , 2020 , 4, 1942-1949	7.8	14
61	Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. <i>Blood</i> , 2020 , 136, 328-338	2.2	14
60	SNP-array lesions in core binding factor acute myeloid leukemia. <i>Oncotarget</i> , 2018 , 9, 6478-6489	3.3	14
59	Targeting IRAK1 in T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015 , 6, 18956-65	3.3	14
58	Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2015 , 100, e196-9	6.6	12
57	Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21). <i>Leukemia and Lymphoma</i> , 2016 , 57, 199-200	1.9	11

56	Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. <i>Cancer</i> , 2015 , 121, 2393-9	6.4	11
55	Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. <i>Cell Reports</i> , 2020 , 30, 739-754.e4	10.6	11
54	Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019 , 3, 3033-3037	7.8	11
53	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. <i>Leukemia</i> , 2020 , 34, 1730-1740	10.7	10
52	Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic Significance. <i>Blood</i> , 2010 , 116, 172-172	2.2	10
51	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. <i>Blood</i> , 2016 , 128, 762-762	2.2	9
50	Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. <i>Cancer Discovery</i> , 2021 ,	24.4	9
49	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019 , 3, 1981-1988	7.8	9
48	Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. <i>Cancer</i> , 2021 , 127, 554-559	6.4	9
47	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. <i>Leukemia Research</i> , 2015 , 39, 1443-7	2.7	8
46	The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. <i>Blood</i> , 2013 , 122, 356-356	2.2	8
45	Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
44	PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL. <i>Blood</i> , 2021 , 138, 1855-1869	2.2	8
43	Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2020 , 105, 1575-1581	6.6	7
42	Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relapsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER). <i>Blood</i> , 2016 , 128, 222-222	2.2	7
41	Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. <i>Blood</i> , 2021 , 138, 507-519	2.2	7
40	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. <i>Blood</i> , 2021 , 137, 524-532	2.2	7
39	Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. <i>Blood</i> , 2021 , 137, 2827-2837	2.2	7

38	Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia. <i>Blood</i> , 2021 , 137, 1697-1701	2.2	6
37	The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. <i>Leukemia Research</i> , 2015 , 39, 453-61	2.7	5
36	Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status.. <i>Blood</i> , 2022 ,	2.2	5
35	Prospective Analysis Of Plasma Cholesterol and Triglycerides In Patients (pts) With Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) During Treatment With The 2nd Generation Tyrosine Kinase Inhibitor (TKI) Nilotinib. <i>Blood</i> , 2013 , 122, 4042-4042	2.2	5
34	Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA). <i>Blood</i> , 2010 , 116, 2183-2183	2.2	4
33	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. <i>Cancer Discovery</i> , 2020 , 10, 1894-1911	24.4	4
32	Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e184-e186	6.6	3
31	Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma. <i>Annals of Hematology</i> , 2015 , 94, 1859-63	3	3
30	Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL - First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss APL Group. <i>Blood</i> , 2010 , 116, 505-505	2.2	3
29	Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol - a Graall Study. <i>Blood</i> , 2016 , 128, 2776-2776	2.2	3
28	Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	3
27	A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis. <i>Leukemia</i> , 2021 , 35, 724-736	10.7	3
26	Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. <i>Haematologica</i> , 2021 , 106, 3240-3244	6.6	3
25	Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial. <i>Blood</i> , 2019 , 134, 1295-1295	2.2	2
24	Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2013 , 122, 620-620	2.2	2
23	Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. <i>Haematologica</i> , 2021 , 106, 1767-1769	6.6	2
22	Outcome and clinicophenotypical features of acute lymphoblastic leukemia/lymphoblastic lymphoma with cutaneous involvement: A multicenter case series. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1166-1170	4.5	2
21	Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS?. <i>Blood</i> , 2010 , 116, 1868-1868	2.2	1

20	Assessment Of Minimal Residual Disease In Acute Myeloblastic Leukemia In Multiparameter Flow Cytometry. <i>Blood</i> , 2013 , 122, 2613-2613	2.2	1
19	Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML. <i>Blood Advances</i> , 2021 , 5, 5258-5268	7.8	1
18	Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. <i>Blood Advances</i> , 2020 , 4, 5322-5335	7.8	1
17	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 74	22.4	1
16	IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL. <i>Blood</i> , 2021 , 137, 1690-1694	2.2	1
15	Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells. <i>Leukemia Research</i> , 2021 , 100, 106490	2.7	1
14	The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs.. <i>Cancer Journal (Sudbury, Mass)</i> , 2022 , 28, 29-36	2.2	0
13	Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial. <i>Blood</i> , 2021 , 138, 3478-3478	2.2	0
12	Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol - a Graall Study. <i>Blood</i> , 2021 , 138, 215-215	2.2	0
11	Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study. <i>Blood</i> , 2021 , 138, 31-31	2.2	0
10	Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup. <i>Blood</i> , 2020 , 136, 10-11	2.2	
9	Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS. <i>Blood</i> , 2020 , 136, 1-2	2.2	
8	Cyclin D2 Dysregulation by Chromosomal Translocations to TCR Loci in T-Cell Acute Lymphoblastic Leukemia (T-ALL).. <i>Blood</i> , 2006 , 108, 2073-2073	2.2	
7	Notch1 Mutations in Adult T Lymphoblastic Lymphoma and T-ALL.. <i>Blood</i> , 2006 , 108, 2286-2286	2.2	
6	NOTCH1/FBXW7 Mutations, but Not Low ERG/BAALC Expression, Identify a Major Subgroup of Adult T-ALL with a Favorable Outcome: a GRAALL Study.. <i>Blood</i> , 2009 , 114, 1568-1568	2.2	
5	Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases. <i>Blood</i> , 2010 , 116, 2171-2171	2.2	
4	A Pediatric Treatment of Ph-Negative Acute Lymphoblastic Leukemia (ALL) Is Effective and Safe In Adolescents and Young Adults (AYAs) until 29 Years of Age. <i>Blood</i> , 2010 , 116, 2125-2125	2.2	
3	Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group. <i>Blood</i> , 2010 , 116, 4171-4171	2.2	

- 2 Epidemiology Of Invasive Aspergillosis (IA) During Induction Therapy In Adults With Acute Lymphoblastic Leukemia (ALL): A Graall-2005 Study. *Blood*, **2013**, 122, 1394-1394 2.2
- 1 Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APL: Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. *Blood*, **2013**, 122, 495-495 2.2